Correction to: Structure based design of non-natural peptidic macrocyclic MCL-1 inhibitors (ACS Medicinal Chemistry Letters (2017) 8 (239-244) DOI: 10.1021/acsmedchemlett.6b00464);Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors

ACS Medicinal Chemistry Letters

Volumn 8, Issue 2, 2017, Pages 239-244

  Johannes, Jeffrey W ^a   Bates, Stephanie ^a   Beigie, Carl ^a   Belmonte, Matthew A ^a   Breen, John ^a   Cao, Shenggen ^c   Centrella, Paolo A ^b   Clark, Matthew A ^b   Cuozzo, John W ^b   Dumelin, Christoph E ^b   Ferguson, Andrew D ^a   Habeshian, Sevan ^b   Hargreaves, David ^a   Joubran, Camil ^a   Kazmirski, Steven ^a   Keefe, Anthony D ^b   Lamb, Michelle L ^a   Lan, Haiye ^c   Li, Yunxia ^c   Ma, Hao ^c   Mlynarski, Scott ^a   Packer, Martin J ^a   Rawlins, Philip B ^a   Robbins, Daniel W ^a   Shen, Haidong ^c   Sigel, Eric A ^b   Soutter, Holly H ^b   Su, Nancy ^a   Troast, Dawn M ^b   Wang, Haiyun ^a   Wickson, Kate F ^a   Wu, Chengyan ^c   Zhang, Ying ^b   Zhao, Qiuying ^c   Zheng, Xiaolan ^a   Hird, Alexander W ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b X Chem Incorporated   (United States)

^c Pharmaron Beijing Co Ltd   (China)

Author keywords

macrocycles; Mcl 1; peptides; protein protein interactions

Indexed keywords

ARGININE; CASPASE 3; MACROCYCLIC COMPOUND; PEPTIDE DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1;

ARTICLE; BINDING KINETICS; CRYSTAL STRUCTURE; CYCLIZATION; DNA LIBRARY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; IC50; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN INTERACTION;

EID: 85013777446     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.7b00397     Document Type: Erratum

References (21)

1. Hanahan, D.; Weinberg; Robert, A. Hallmarks of Cancer: The Next Generation Cell 2011, 144, 646-674 10.1016/j.cell.2011.02.013
2. Taylor, R. C.; Cullen, S. P.; Martin, S. J. Apoptosis: controlled demolition at the cellular level Nat. Rev. Mol. Cell Biol. 2008, 9, 231-41 10.1038/nrm2312
3. Czabotar, P. E.; Lessene, G.; Strasser, A.; Adams, J. M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy Nat. Rev. Mol. Cell Biol. 2014, 15, 49-63 10.1038/nrm3722
4. Oda, E.; Ohki, R.; Murasawa, H.; Nemoto, J.; Shibue, T.; Yamashita, T.; Tokino, T.; Taniguchi, T.; Tanaka, N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis Science 2000, 288, 1053-8 10.1126/science.288.5468.1053
5. Roberts, A. W.; Davids, M. S.; Pagel, J. M.; Kahl, B. S.; Puvvada, S. D.; Gerecitano, J. F.; Kipps, T. J.; Anderson, M. A.; Brown, J. R.; Gressick, L.; Wong, S.; Dunbar, M.; Zhu, M.; Desai, M. B.; Cerri, E.; Heitner Enschede, S.; Humerickhouse, R. A.; Wierda, W. G.; Seymour, J. F. Targeting Bcl2 with venetoclax in relapsed chronic lymphocytic leukemia N. Engl. J. Med. 2016, 374, 311-22 10.1056/NEJMoa1513257
6. Czabotar, P. E.; Lee, E. F.; van Delft, M. F.; Day, C. L.; Smith, B. J.; Huang, D. C.; Fairlie, W. D.; Hinds, M. G.; Colman, P. M. Structural insights into the degradation of Mcl-1 induced by BH3 domains Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 6217-22 10.1073/pnas.0701297104
7. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat. Rev. Drug Discovery 2004, 3, 301-17 10.1038/nrd1343
8. Arkin, M. R.; Tang, Y.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality Chem. Biol. 2014, 21, 1102-14 10.1016/j.chembiol.2014.09.001
9. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-9 10.1038/nature06526
10. Raj, M.; Bullock, B. N.; Arora, P. S. Plucking the high hanging fruit: a systematic approach for targeting protein-protein interactions Bioorg. Med. Chem. 2013, 21, 4051-7 10.1016/j.bmc.2012.11.023
11. Beekman, A. M.; Howell, L. A. Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1 ChemMedChem 2016, 11, 802-13 10.1002/cmdc.201500497
12. https://clinicaltrials.gov/ct2/show/NCT02675452 (accessed September 30th, 2016).
13. Clark, M. A.; Acharya, R. A.; Arico-Muendel, C. C.; Belyanskaya, S. L.; Benjamin, D. R.; Carlson, N. R.; Centrella, P. A.; Chiu, C. H.; Creaser, S. P.; Cuozzo, J. W.; Davie, C. P.; Ding, Y.; Franklin, G. J.; Franzen, K. D.; Gefter, M. L.; Hale, S. P.; Hansen, N. J.; Israel, D. I.; Jiang, J.; Kavarana, M. J.; Kelley, M. S.; Kollmann, C. S.; Li, F.; Lind, K.; Mataruse, S.; Medeiros, P. F.; Messer, J. A.; Myers, P.; O'Keefe, H.; Oliff, M. C.; Rise, C. E.; Satz, A. L.; Skinner, S. R.; Svendsen, J. L.; Tang, L.; van Vloten, K.; Wagner, R. W.; Yao, G.; Zhao, B.; Morgan, B. A. Design, synthesis and selection of DNA-encoded small-molecule libraries Nat. Chem. Biol. 2009, 5, 647-54 10.1038/nchembio.211
14. Litovchick, A.; Dumelin, C. E.; Habeshian, S.; Gikunju, D.; Guié, M.-A.; Centrella, P.; Zhang, Y.; Sigel, E. A.; Cuozzo, J. W.; Keefe, A. D.; Clark, M. A. Encoded Library Synthesis Using Chemical Ligation and the Discovery of sEH Inhibitors from a 334-Million Member Library Sci. Rep. 2015, 5, 10916 10.1038/srep10916
15. Friberg, A.; Vigil, D.; Zhao, B.; Daniels, R. N.; Burke, J. P.; Garcia-Barrantes, P. M.; Camper, D.; Chauder, B. A.; Lee, T.; Olejniczak, E. T.; Fesik, S. W. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design J. Med. Chem. 2013, 56, 15-30 10.1021/jm301448p
16. Fang, C.; D'Souza, B.; Thompson, C. F.; Clifton, M. C.; Fairman, J. W.; Fulroth, B.; Leed, A.; McCarren, P.; Wang, L.; Wang, Y.; Feau, C.; Kaushik, V. K.; Palmer, M.; Wei, G.; Golub, T. R.; Hubbard, B. K.; Serrano-Wu, M. H. Single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1) ACS Med. Chem. Lett. 2014, 5, 1308-12 10.1021/ml500388q
17. Bruncko, M.; Wang, L.; Sheppard, G. S.; Phillips, D. C.; Tahir, S. K.; Xue, J.; Erickson, S.; Fidanze, S.; Fry, E.; Hasvold, L.; Jenkins, G. J.; Jin, S.; Judge, R. A.; Kovar, P. J.; Madar, D.; Nimmer, P.; Park, C.; Petros, A. M.; Rosenberg, S. H.; Smith, M. L.; Song, X.; Sun, C.; Tao, Z. F.; Wang, X.; Xiao, Y.; Zhang, H.; Tse, C.; Leverson, J. D.; Elmore, S. W.; Souers, A. J. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity J. Med. Chem. 2015, 58, 2180-94 10.1021/jm501258m
18. Burke, J. P.; Bian, Z.; Shaw, S.; Zhao, B.; Goodwin, C. M.; Belmar, J.; Browning, C. F.; Vigil, D.; Friberg, A.; Camper, D. V.; Rossanese, O. W.; Lee, T.; Olejniczak, E. T.; Fesik, S. W. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design J. Med. Chem. 2015, 58, 3794-805 10.1021/jm501984f
19. Pelz, N. F.; Bian, Z.; Zhao, B.; Shaw, S.; Tarr, J. C.; Belmar, J.; Gregg, C.; Camper, D. V.; Goodwin, C. M.; Arnold, A. L.; Sensintaffar, J. L.; Friberg, A.; Rossanese, O. W.; Lee, T.; Olejniczak, E. T.; Fesik, S. W. Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods J. Med. Chem. 2016, 59, 2054-66 10.1021/acs.jmedchem.5b01660
20. Kotschy, A.; Szlavik, Z.; Murray, J.; Davidson, J.; Maragno, A. L.; Le Toumelin-Braizat, G.; Chanrion, M.; Kelly, G. L.; Gong, J.-N.; Moujalled, D. M.; Bruno, A.; Csekei, M.; Paczal, A.; Szabo, Z. B.; Sipos, S.; Radics, G.; Proszenyak, A.; Balint, B.; Ondi, L.; Blasko, G.; Robertson, A.; Surgenor, A.; Dokurno, P.; Chen, I.; Matassova, N.; Smith, J.; Pedder, C.; Graham, C.; Studeny, A.; Lysiak-Auvity, G.; Girard, A.-M.; Gravé, F.; Segal, D.; Riffkin, C. D.; Pomilio, G.; Galbraith, L. C. A.; Aubrey, B. J.; Brennan, M. S.; Herold, M. J.; Chang, C.; Guasconi, G.; Cauquil, N.; Melchiore, F.; Guigal-Stephan, N.; Lockhart, B.; Colland, F.; Hickman, J. A.; Roberts, A. W.; Huang, D. C. S.; Wei, A. H.; Strasser, A.; Lessene, G.; Geneste, O. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models Nature 2016, 538, 477-482 10.1038/nature19830
21. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-90 10.1038/nrd2445